NRIX
Nurix Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 8 ▲ Nurix Therapeutics announced a global collaboration with Roche to co…
- Jun 8 ▼ Wells Fargo downgrades
- Jun 8 Contract: Nurix Therapeutics Announces Global Collaboration with Roc…
- Jul 21 Contract: Nurix Therapeutics Announces HSR Clearance of Global Colla…
- Jul 30 to Aug 5 ▼ 4 days of insider sells: $863.9K by 3 insiders, avg $23.66
- Sep 1 to Sep 2 ▼ 2 days of insider sells: $186.1K by 2 insiders, avg $25.70
- Oct 2 ▼ 1 insider sell $134.1K at $23.19
- Oct 5 Contract: Nurix Therapeutics Announces Second Research Term Extensio…
- Oct 5 ▲ Nurix Therapeutics announced a two-year extension of the research te…
- Oct 13 ▲ Nurix Therapeutics reported Q3 2026 revenue of $673.1M (vs $7.9M YoY…
- Oct 14 to Oct 15 ▼ 2 days of insider sells: $564.8K by 2 insiders, avg $23.50
- Oct 30 to Nov 4 ▼ 4 days of insider sells: $827.8K by 3 insiders, avg $24.58
Signal stack
Where each data set points today.
- InsidersBEARISH
4 insiders sold $2.6M.
- InstitutionsBULLISH
Q2 2026: 26 added (1 new), 16 trimmed or exited. Largest new: Arrowstreet Capital, Limited Partnership $11.6M.
- AnalystsBULLISH
18 of 20 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.369 → $1.508 over 90 days. 2 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest −8.1% to 18.94M shares. 7.2 days to cover, ≈17.3% of shares.
- TrendDOWNTREND
36% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 5.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| Rubric Capital Management LP | DOUBLED | $175.3M |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | $131.9M |
| Capital World Investors | DOUBLED | $43.4M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $36.0M |
| DIMENSIONAL FUND ADVISORS LP | ADD | $34.7M |
| GOLDMAN SACHS GROUP INC | TRIM | $19.7M |
| RAYMOND JAMES FINANCIAL INC | ADD | $14.4M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | NEW | $11.6M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
20 analystsPrice is below the lowest target. Median implies +134%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 4, 2026 | Wells Fargo MAINTAIN | Equal-Weight |
| Oct 16, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Oct 13, 2026 | RBC Capital MAINTAIN | Outperform |
| Oct 13, 2026 | Oppenheimer MAINTAIN | Outperform |
| Oct 13, 2026 | Truist Securities MAINTAIN | Buy |
| Oct 13, 2026 | Baird MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
van Houte Hans Chief Financial Officer Nov 4, 2026 | SELL | $50.8K |
van Houte Hans Chief Financial Officer Nov 4, 2026 | SELL | $23.8K |
Ring Christine Chief Legal Officer Nov 3, 2026 | SELL | $157.9K |
Ring Christine Chief Legal Officer Nov 2, 2026 | SELL | $245.2K |
Ring Christine Chief Legal Officer Nov 2, 2026 | EXERCISE | $50.5K |
Ring Christine Chief Legal Officer Nov 2, 2026 | SELL | $28.8K |
Hansen Gwenn Chief Scientific Officer Nov 2, 2026 | EXERCISE | $2.7K |
Hansen Gwenn Chief Scientific Officer Nov 2, 2026 | SELL | $38.9K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $1.51 | -$0.64–$5.26 | +509.2% | $287.9M |
| Next Q | -$0.59 | -$0.59–-$0.59 | -34.1% | $15.0M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | -$1.28 | -$2.48–-$0.62 | -19.7% | $123.2M |
Short side
FINRA· Oct 30, 2026SecBot reports
30 filings · 3 press releases · 3 bullish · 3 bearish · 24 neutral- NEUTRAL SC 13G/ANov 16, 2026
Vestal Point Capital, LP filed an amended Schedule 13G disclosing a 6.4% passive stake in Nurix Therapeutics as of September 30, 2026, representing 7,025,000 shares. This is a new position above the 5% threshold, making Vestal Point the largest disclosed passive holder among recent filings.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
T. Rowe Price Associates filed an amended Schedule 13G disclosing a 4.4% passive stake in Nurix Therapeutics as of September 30, 2026, representing 4,570,774 shares. This is a decrease from a prior position above 5%, as the prior filing by Deep Track Capital showed a 5.49% stake at the same date.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Deep Track Capital, LP filed an amended Schedule 13G disclosing a 5.49% passive stake in Nurix Therapeutics as of September 30, 2026, representing 6,000,000 shares. This is an increase from a prior position below 5%, but remains a passive filing with no intent to influence control.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 5, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G disclosing a 4.2% passive stake in Nurix…
Fidelity's reduction below 5% removes any filing obligation for further changes, but the passive nature of the stake means no activist pressure. Monitor for any future 13D conversion if the…
All NRIX filing & press-release reports (33)
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 5, 2026
- CLUSTER reportNov 4, 2026
- 144 reportNov 4, 2026
- 144 reportNov 3, 2026
- 8-K reportNov 3, 2026
- CLUSTER reportNov 2, 2026
- 144 reportNov 2, 2026
- CLUSTER reportOct 15, 2026
- 144 reportOct 14, 2026
- 8-K reportOct 13, 2026
- PRESS-RELEASE reportOct 5, 2026
- SC 13G reportSep 23, 2026
- CLUSTER reportSep 2, 2026
- CLUSTER reportAug 5, 2026
- CLUSTER reportAug 5, 2026
- CLUSTER reportAug 4, 2026
- CLUSTER reportAug 3, 2026
- CLUSTER reportJul 30, 2026
- PRESS-RELEASE reportJul 9, 2026
- CLUSTER reportJul 2, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportJun 8, 2026
- PRESS-RELEASE reportJun 8, 2026
- CLUSTER reportApr 30, 2026
- CLUSTER reportApr 30, 2026
- CLUSTER reportApr 30, 2026
- CLUSTER reportApr 30, 2026
- PRESS-RELEASE reportApr 22, 2026
- PRESS-RELEASE reportApr 8, 2026
- 8-K reportApr 8, 2026